Concerns Over Shareholder Rights in Recent Corporate Sales of SEM, UNF, CNTA, and ASRT

Investigation into Shareholder Transactions

In recent months, several companies have come under scrutiny for their acquisition deals, sparking significant concerns about the potential impact on shareholder rights. Halper Sadeh LLC, a law firm specializing in investor rights, is currently investigating Select Medical Holdings Corporation (NYSE: SEM), UniFirst Corporation (NYSE: UNF), Centessa Pharmaceuticals plc (NASDAQ: CNTA), and Assertio Holdings, Inc. (NASDAQ: ASRT) for what may be serious violations of federal securities laws and fiduciary duties owed to shareholders. This inquiry has raised questions about whether these companies are ensuring fair treatment and proper financial remuneration for their stakeholders during these transitional phases.

Specific Cases Under Review

1. Select Medical Holdings Corporation (SEM)
Select Medical has accepted a buyout offer from a consortium led by its executives and directors at a price of $16.50 per share in cash. While this may seem beneficial on the surface, critics argue that this deal might not fully reflect the company's true market value. Investors are urged to assess if they are indeed receiving fair compensation for their shares.

2. UniFirst Corporation (UNF)
The proposed acquisition of UniFirst by Cintas Corporation involves payments of $155 per UniFirst share, combined with a stock swap. Although the terms appear to suggest a premium, concerns emerge regarding the influence of board members and whether shareholders have been adequately consulted. Halper Sadeh is encouraging UniFirst shareholders to evaluate their rights and options in light of these developments.

3. Centessa Pharmaceuticals (CNTA)
Centessa’s agreement to sell to Eli Lilly includes a cash payment of $38 per share along with additional contingent rewards that depend on specific milestones. The complexity of this deal raises red flags about its suitability for shareholders. Investors are being prompted to consider how these contingent rights impact the current agreement in comparison to potentially better offers that might not have been explored.

4. Assertio Holdings (ASRT)
Finally, Assertio’s deal with Garda Therapeutics proposes a cash arrangement of $18 per share, accompanied by a contingent value right. As with the other companies, there are questions surrounding whether this structure adequately benefits shareholders and if lower offers might limit better financial transactions.

Shareholder Rights Are Paramount

Halper Sadeh LLP is reaching out to the shareholders of these companies to make them aware of their rights regarding these transitions. Shareholders are encouraged to seek legal recourse, which may include pursuing higher bid amounts or demanding further disclosures regarding the deals. Under U.S. laws, shareholders are entitled to a degree of protection against fiduciary breaches, and Halper Sadeh is ready to advocate for their interests on a contingency fee basis, meaning they only collect fees if they successfully secure restitution or favorable terms.

As the dynamics of corporate America continue to evolve through mergers and acquisitions, the importance of vigilant shareholder representation becomes increasingly significant. Halper Sadeh, representing personal investors worldwide who have faced various corporate misconduct, understands the complexities of financial reforms and the substantial recovery efforts that often come with such legal principles. Investors unsure of their rights or the sufficiency of their financial gratifications amid these transitions are wise to consult a legal professional who specializes in these matters.

In this climate, shareholders of SEM, UNF, CNTA, and ASRT are encouraged to stay informed about their rights and the ongoing investigations to make well-informed decisions regarding their investments.